Launch of MedPark Allo, an Allogeneic Bone Graft
MedPark Co., Ltd., a regenerative medicine specialist, announced that it will begin full-scale supply of 'MedPark Allo,' an allogeneic bone graft material designed to fit the shape of bone defects after hydration, to medical institutions in Korea.Medpark Allo is a Grade 4 medical device based on allogeneic bone, containing over 80% freeze-dried allogeneic bone (FDBA) main chip and combined with a hydrogel carrier. It was included as a non-reimbursed therapeutic material in the Ministry of Health and Welfare notice implemented on September 1, and Medpark plans to expand product supply and usage information in line with the procedures for introducing new treatment materials at medical institutions.The greatest feature of Medpark Alo is that it combines the properties of allogeneic bone materials with the ease of handling and application required during actual surgical procedures.The product applies Medpark's proprietary S1 technology, which hydrates according to approved usage methods and allows medical staff to mold the bone defect area according to the size and shape of the bone defect. It is designed to adhere firmly and stabilize the treatment area, maintaining the initial shape (Shape Retention) at the application site.While conventional bone grafts have mainly focused on the biological properties of the material itself, the allogeneic bone graft Medpark Alo considers how medical staff shape the graft material during actual surgery and maintain its shape even after applying it in the desired position.Medpark Alo can be sculpted to fit the size and shape of various bone defects, making it suitable for various bone defect and reconstructive surgical settings including the spine, lower and upper limbs, shoulders and clavicles, elbows and wrists, hips, knees, and ankles.In particular, the company expects to offer a new option in surgical environments where stable application and shape maintenance of bone graft materials are required, such as fractures, bone defects, nonunion, and spinal fusion.Additionally, as a product approved as a medical device, it reduces the administrative burden required for the use of existing human tissue grafts, thereby improving convenience in actual clinical settings.With this notice, Medpark plans to expand product supply according to each medical institution's introduction procedures and schedule, and provide information on approved uses, usage methods, and product specifications. After launch, Medpark Alo plans to gradually and continuously accumulate its own clinical and academic data within the scope of approval.A Medpark representative stated, "Medpark Alo focused on showing in detail how the product can be shaped and applied, taking into account the actual needs of surgical sites," adding, "We plan to expand supply to medical institutions and provide product usage information, and also expand related academic activities targeting key medical staff."Key Specifications of MedPark AlloComposition: Contains over 80% Freeze-Dried Bone Allograft (FDBA) bone chips combined with a specialized hydrogel carrier.Classification: Approved as a high-standard Class 4 medical device.Core Technology: Built on MedPark's proprietary "S1 Technology", which enables the graft material to become moldable and cohesive upon hydration. Source: http://www.doctorstimes.com/news/articleView.html?idxno=239882
LEARN MORE 
